Relmada Therapeutics (RLMD) EBT Margin (2012 - 2023)
Relmada Therapeutics' EBT Margin came in at -2030.62% for Q4 2023, up 1549.04 percentage points from -3579.66% a year earlier but down 413.36 percentage points from the prior quarter.
Powered by 
Analysis
Relmada Therapeutics (RLMD) EBT Margin (2012 - 2023) Analysis & Trends
For FY2023, Relmada Therapeutics' EBT Margin was -1912.97%, up 5862.18 percentage points from FY2022.
- Going back by year, EBT Margin was -7775.15% in FY2022 (+14549.71 pp) and -22324.86% in FY2021.
- The five-year range for quarterly EBT Margin is -95047.20% (Q4 2021) to -1617.26% (Q3 2023).
- Year-over-year, EBT Margin has increased for five consecutive quarters, with an average year-over-year change of +24477.11 percentage points over the last five quarters.
- Business Quant data shows RLMD's EBT Margin at -1617.26% (Q3 2023), -1808.95% (Q2 2023) and -4981.48% (Q1 2023) in the three quarters before Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 0.13% |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 27.75% |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 29.63% |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 18.19% |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 45.21% |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 36.90% |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 20.41% |
| 10 | Relmada Therapeutics | 473.10 Mn | -85.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -2,030.62% |
| Sep 30, 2023 | -1,617.26% |
| Jun 30, 2023 | -1,808.95% |
| Mar 31, 2023 | -4,981.48% |
| Dec 31, 2022 | -3,579.66% |
| Sep 30, 2022 | -14,564.87% |
| Jun 30, 2022 | -11,051.05% |
| Mar 31, 2022 | -12,160.73% |
| Dec 31, 2021 | -95,047.20% |
| Dec 31, 2020 | -9,329.66% |
| Sep 30, 2020 | -4,629.86% |
| Sep 30, 2019 | -9,677.96% |
| Mar 31, 2019 | -16,952.16% |
| Sep 30, 2017 | -177.52% |
| Jun 30, 2017 | -865,477.67% |
| Mar 31, 2017 | -482,653.70% |
| Jun 30, 2016 | -163,632.54% |
| Mar 31, 2016 | -353,096.14% |
| Jun 30, 2015 | -910,343.02% |
| Mar 31, 2015 | -198,697.52% |
API Access
Relmada Therapeutics EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();